IceCure Medical (ICCM) EBITDA (2020 - 2026)

IceCure Medical (ICCM) has 7 years of EBITDA data on file, last reported at $4.2 million in Q1 2026.

• EBITDA for Q1 2026 came in at $4.2 million, up 16.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.7 million (changed 0.12% YoY), and the FY2025 annual result was $15.1 million, down 3.84% from the prior year.
• EBITDA rose to $4.2 million in Q1 2026 per ICCM's latest filing, from $4.2 million in the prior quarter.
• Over five years, EBITDA peaked at $4.5 million in Q4 2024 and troughed at -$29.5 million in Q4 2022.
• A 5-year average of $160117.6 and a median of $4.1 million in 2023 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 270.91% in 2022 and fell as far as 81.04% in 2022.
• A 5-year view of EBITDA shows it stood at -$29.5 million in 2022, then climbed by 6.12% to -$27.7 million in 2023, then surged by 116.31% to $4.5 million in 2024, then slipped by 6.83% to $4.2 million in 2025, then grew by 0.74% to $4.2 million in 2026.
• Business Quant data shows ICCM's EBITDA at $4.2 million in Q1 2026, $4.2 million in Q4 2025, and $3.8 million in Q3 2025.